Adaptimmune Therapeutics (NASDAQ:ADAP) Earns Buy Rating from Analysts at StockNews.com
StockNews.com assumed coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) in a research report released on Wednesday. The brokerage issued a buy rating on the biotechnology company’s stock. ADAP has been the subject of a number of other research reports. Guggenheim dropped their target price on Adaptimmune Therapeutics from $3.00 to $1.75 and […]
StockNews.com assumed coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) in a research report released on Wednesday. The brokerage issued a buy rating on the biotechnology company’s stock. ADAP has been the subject of a number of other research reports. Guggenheim dropped their target price on Adaptimmune Therapeutics from $3.00 to $1.75 and […]
